Aude-Hélène Capietto
Research Subjects
Research Interests
Aude-Hélène Capietto has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Lélia Delamarre
Cancer Immunology Department, Genentech Inc, South San Francisco, CA, USA
18 shared publications- Alex T. Ritter
Genentech, South San Francisco, USA
17 shared publications Dorothee Nickles
17 shared publicationsHuizhong Xiong
17 shared publicationsIra Mellman
17 shared publications- Justin Elstrott
Department of Translational Imaging, Genentech, Inc
17 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Additional material and methods
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Additional material and methods
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Supplemental Figures Showing: Fig. S1: CD8 T cells co-expressing PD1, LAG3 and TIM3 are present at different frequencies in MC38 and EMT6 tumors and represent activated cells. Fig. S2: CD8 T cells co-expressing inhibitory receptors are enriched in antigen-experienced and activated cells relative to the PD1- subset. Fig. S3: Majority of CD8 T cells in blood of MC38 and EMT6 tumor bearing mice lack PD1 and T-bet expression. Fig. S4: Anti-PD-L1 treatment increases the activity and cytolytic potential of PD1+ CD8 T cell subsets in MC38 and EMT6 tumors. Fig. S5: JC and 4T1 tumors do not respond to anti-PD-L1 treatment. Fig. S6: CD8 T cells co-expressing PD1, LAG3 and TIM3 are highly activated in JC and 4T1 tumors. Table S1: List of flow cytometry markers used for univariate linear regression analysis in Supplementary table 2. Table S2: Top parameters correlated with response to anti-PD-L1.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Supplemental Figures Showing: Fig. S1: CD8 T cells co-expressing PD1, LAG3 and TIM3 are present at different frequencies in MC38 and EMT6 tumors and represent activated cells. Fig. S2: CD8 T cells co-expressing inhibitory receptors are enriched in antigen-experienced and activated cells relative to the PD1- subset. Fig. S3: Majority of CD8 T cells in blood of MC38 and EMT6 tumor bearing mice lack PD1 and T-bet expression. Fig. S4: Anti-PD-L1 treatment increases the activity and cytolytic potential of PD1+ CD8 T cell subsets in MC38 and EMT6 tumors. Fig. S5: JC and 4T1 tumors do not respond to anti-PD-L1 treatment. Fig. S6: CD8 T cells co-expressing PD1, LAG3 and TIM3 are highly activated in JC and 4T1 tumors. Table S1: List of flow cytometry markers used for univariate linear regression analysis in Supplementary table 2. Table S2: Top parameters correlated with response to anti-PD-L1.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Movie S2 from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S2 from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Movie S1 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1+LAG3+TIM3+ CD8 T cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1+LAG3+TIM3+ CD8 T cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets
Anti-Gr1 Ab treatment reduces soft tissue tumor growth
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets
Anti-Gr1 Ab treatment reduces soft tissue tumor growth
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Movie S2 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S2 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Movie S2 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S2 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Cytotoxicity assay with sorted PD1- CD8 T cells